Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Dow
Deloitte
Julphar
Colorcon
Cipla
Federal Trade Commission
Moodys
Chubb
US Army

Generated: October 17, 2017

DrugPatentWatch Database Preview

WYETH PHARMS INC Company Profile

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS INC, and what generic alternatives to WYETH PHARMS INC drugs are available?

WYETH PHARMS INC has thirty-one approved drugs.

There are eighteen US patents protecting WYETH PHARMS INC drugs on WYETH PHARMS INC drugs in the past three years.

There are three hundred and ten patent family members on WYETH PHARMS INC drugs in sixty-four countries and twenty-four supplementary protection certificates in ten countries.

Summary for Applicant: WYETH PHARMS INC

International Patents:310
US Patents:18
Tradenames:29
Ingredients:19
NDAs:31
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc
PRISTIQ
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL021992-002Feb 29, 2008ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
CORDARONE
amiodarone hydrochloride
TABLET;ORAL018972-001Dec 24, 1985DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PROTONIX
pantoprazole sodium
TABLET, DELAYED RELEASE;ORAL020987-002Jun 12, 2001ABRXYesNo► Subscribe► SubscribeY► Subscribe
Wyeth Pharms Inc
INDERAL
propranolol hydrochloride
TABLET;ORAL016418-010Oct 18, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO (PREMARIN;CYCRIN)
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020303-001Dec 30, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
PREMARIN
estrogens, conjugated
TABLET;ORAL004782-006Jul 16, 2003RXYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
LODINE
etodolac
CAPSULE;ORAL018922-003Jan 31, 1991DISCNYesNo► Subscribe► Subscribe► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-001Feb 24, 1998RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
ZOSYN IN PLASTIC CONTAINER
piperacillin sodium; tazobactam sodium
INJECTABLE;INJECTION050750-003Feb 24, 1998RXYesYes► Subscribe► SubscribeY ► Subscribe
Wyeth Pharms Inc
PROTONIX IV
pantoprazole sodium
INJECTABLE;IV (INFUSION)020988-001Mar 22, 2001APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Wyeth Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc
PREMARIN
estrogens, conjugated
TABLET;ORAL004782-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020527-001Nov 17, 1995► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-001Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
MYLOTARG
gemtuzumab ozogamicin
INJECTABLE;INJECTION021174-001May 17, 2000► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO (PREMARIN;CYCRIN)
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020303-001Dec 30, 1994► Subscribe► Subscribe
Wyeth Pharms Inc
TRIPHASIL-28
ethinyl estradiol; levonorgestrel
TABLET;ORAL-28019190-001Nov 1, 1984► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-004Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
PREMPRO
estrogens, conjugated; medroxyprogesterone acetate
TABLET;ORAL-28020527-003Jan 9, 1998► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-002Oct 20, 1997► Subscribe► Subscribe
Wyeth Pharms Inc
EFFEXOR XR
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020699-003Oct 20, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for WYETH PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
desvenlafaxine succinate
Extended-release Tablets 25 mg
PRISTIQ
5/8/2015
desvenlafaxine succinate
Extended-release Tablets50 mg and 100 mg
PRISTIQ
2/29/2012
piperacillin sodium and tazobactam sodium
For Injection12 g/1.5 g per vial (pharmacy bulk)
ZOSYN
12/6/2011
levonorgestrel and ethinyl estradiol
Tablets0.09 mg/0.02 mg
LYBREL
10/5/2007
venlafaxine hydrochloride
Extended-release Tablets37.5 mg, 75 mg and 150 mg
EFFEXOR XR
5/3/2007
venlafaxine hydrochloride
Tablets25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg
EFFEXOR
11/3/2005
pantoprazole sodium
Delayed-release Tablets20 mg and 40 mg
PROTONIX
2/2/2004

Non-Orange Book Patents for Wyeth Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,026,508Succinate salt of O-desmethyl-venlafaxine► Subscribe
7,498,312Compositions containing piperacillin and tazobactam useful for injection► Subscribe
7,291,347Succinate salt of O-desmethyl-venlafaxine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Wyeth Pharms Inc Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9922724► Subscribe
Germany602004010862► Subscribe
Norway971206► Subscribe
Spain2322790► Subscribe
Slovenia1339430► Subscribe
Eurasian Patent Organization007602► Subscribe
Switzerland695185► Subscribe
Portugal797991► Subscribe
Hungary0303278► Subscribe
Finland101598► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Wyeth Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C/GB96/056United Kingdom► SubscribePRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Covington
Argus Health
Mallinckrodt
Harvard Business School
Fish and Richardson
Merck
Colorcon
Accenture
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot